Yifan Pharmaceutical (002019.SZ): Ambroxol Oral Solution Obtains Drug Registration Certificate.

Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" for the approval and issuance of the oral solution of ambroxol by the National Medical Products Administration on March 10, 2025. It is reported that ambroxol oral solution is a medication for respiratory system diseases. It is used to treat acute and chronic respiratory diseases related to spastic contractions, changes in secretion formation, and impaired secretion transport, especially spastic bronchitis, emphysematous bronchitis, and bronchial asthma.